Lenomorelin

Ghrelin Receptor Agonist (acylated Ghrelin Analogue)Rx: InvestigationalCompound: Investigational

Also known as: Acylated ghrelin (synthetic), Ghrelin (human), TZP-101, Ulimorelin (related compound)

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Lenomorelin (synthetic acylated ghrelin) is an investigational peptide being studied primarily for gastroparesis, cachexia, anorexia associated with chronic illness, and postoperative gastrointestinal dysmotility. It mimics endogenous acylated ghrelin to stimulate GH release and enhance gastric emptying.

Mechanism of Action

Lenomorelin is a synthetic form of acylated ghrelin that binds to and activates the growth hormone secretagogue receptor 1a (GHSR-1a), stimulating growth hormone secretion from the pituitary, promoting appetite, and modulating gastrointestinal motility.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Postoperative ileus managementGastrointestinal MotilityModerate
  • Improvement of gastroparesis symptomsGastrointestinal MotilityModerate
  • Stimulation of growth hormone secretionEndocrineHigh
  • Treatment of cancer cachexia / anorexiaNutritional/metabolicModerate
  • Short bowel syndrome nutritional supportNutritional/metabolicLow

Contraindications

  • Active malignancy with hormone-sensitive tumorsOncologyHigh
  • Uncontrolled Diabetes MellitusMetabolic / EndocrineModerate
  • Acromegaly or active pituitary adenomaEndocrineHigh
  • Known hypersensitivity to ghrelin or its analoguesAllergic/immunologicHigh

Adverse Effects

  • HyperglycemiaMetabolicCommonAbnormally high blood glucose
  • Injection site reactionsLocalCommon
  • Increased appetite/weight gainMetabolicCommon
  • FlushingVascularUncommonWarmth and redness of the skin
  • Cortisol and prolactin elevationEndocrineUncommon
  • NauseaGastrointestinalCommonFeeling of sickness or urge to vomit

Drug Interactions

  • Insulin / antidiabetic agentsModerate
  • CorticosteroidsLow
  • Growth hormone / IGF-1 therapiesModerate

Population Constraints

  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative
  • Pregnant womenReproductiveRelative
  • Patients with renal or hepatic impairmentOrgan FunctionRelative

Regulatory Status

  • European UnionInvestigationalNo EMA marketing authorization; studied in European clinical trials.
  • United StatesInvestigationalHas been studied in FDA-registered clinical trials (e.g., gastroparesis, cachexia) but not approved.
  • United KingdomInvestigationalNo MHRA approval; remains a research compound.

Not approved by FDA, EMA, or other major regulatory agencies. Has been studied in clinical trials for gastroparesis and cancer cachexia. Developed under the INN 'lenomorelin'; previously investigated by Æterna Zentaris and other sponsors.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack